Submissions from 2022
A phase 1 multiple-ascending dose study to evaluate the safety and tolerability of XmAb23104 (PD-1 x ICOS) in subjects with selected advanced solid tumors (DUET-3)., Mehmet Akce, Rom Leidner, and See full list of authors in comments
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd - 4th, 2021, Italy)., Paolo A Ascierto, Sanjiv S Agarwala, Christian Blank, Corrado Caracò, Richard D Carvajal, Marc S Ernstoff, Soldano Ferrone, Bernard A Fox, Thomas F Gajewski, Claus Garbe, Jean-Jacques Grob, Omid Hamid, Michelle Krogsgaard, Roger S Lo, Amanda W Lund, Gabriele Madonna, Olivier Michielin, Bart Neyns, Iman Osman, Solange Peters, Poulikos I Poulikakos, Sergio A Quezada, Bradley Reinfeld, Laurence Zitvogel, Igor Puzanov, and Magdalena Thurin
Perspectives in Immunotherapy: meeting report from the Immunotherapy Bridge, December 1st-2nd, 2021., Paolo A Ascierto, Antonio Avallone, Nina Bhardwaj, Carlo Bifulco, Sergio Bracarda, Joshua D Brody, Luigi Buonaguro, Sandra Demaria, Leisha A Emens, Robert L Ferris, Jérôme Galon, Samir N Khleif, Christopher A Klebanoff, Tamara Laskowski, Ignacio Melero, Chrystal M Paulos, Sandro Pignata, Marco Ruella, Inge Marie Svane, Janis M Taube, Bernard A Fox, Patrick Hwu, and Igor Puzanov
The "Great Debate" at Immunotherapy Bridge 2021, December 1st-2nd, 2021., Paolo A Ascierto, Lisa H Butterfield, Olivera J Finn, Andrew Futreal, Omid Hamid, Theresa LaVallee, Michael A Postow, Igor Puzanov, Jeffrey Sosman, Bernard A Fox, and Patrick Hwu
Fluorescence tagging to monitor CD8 T cell recirculation from the tumor to the tumor-draining lymph node: the impact of focal radiation therapy on recirculation, TC Blair, Brian D. Piening, Marka R Crittenden, Michael J. Gough, and See full list of authors in comments
ICOS is upregulated on T cells following radiation and agonism combined with radiation results in enhanced tumor control., Tiffany Blair, Jason Baird, Shelly Bambina, Gwen Kramer, Monica Gostissa, Christopher J Harvey, Michael J Gough, and Marka R Crittenden
Fluorescent tracking identifies key migratory dendritic cells in the lymph node after radiotherapy., Tiffany Blair, Shelly Bambina, Gwen Kramer, Alexa K Dowdell, Alejandro F Alice, Jason R Baird, Amanda W Lund, Brian D. Piening, Marka R Crittenden, and Michael J. Gough
Praluzatamab ravtansine, a CD166-targeting antibody-drug conjugate, in patients with advanced solid tumors: an open-label phase 1/2 trial., Valentina Boni, Mary J Fidler, Hendrik-Tobias Arkenau, Alexander Spira, Funda Meric-Bernstam, Nataliya Uboha, Rachel E Sanborn, Randy F Sweis, Patricia LoRusso, Misako Nagasaka, Javier Garcia-Corbacho, Shadia Jalal, James J Harding, Stella K Kim, Iris H C Miedema, Danielle J Vugts, Marc C Huisman, Gerben J C Zwezerijnen, Guus A M S van Dongen, Catharina W Menke-van der Houven van Oordt, Song Wang, Tam Dang, Ivan A Zein, Olga Vasiljeva, Susan K Lyman, Virginia Paton, Alison Hannah, and Joyce F Liu
Changes in T-cell subsets and clonal repertoire during chemoimmunotherapy with pembrolizumab and paclitaxel or capecitabine for metastatic triple-negative breast cancer., Brie Chun, Joanna Pucilowska, Shu-Ching Chang, Isaac Kim, Benjamin Nikitin, Yoshinobu Koguchi, William L. Redmond, Brady Bernard, Venkatesh Rajamanickam, Nathan Polaske, Paul A Fields, Valerie Conrad, Mark Schmidt, Walter Urba, Alison Conlin, Heather L McArthur, and David B Page
CT243 / 4 - Phase 1 study of TAK-676 + pembrolizumab following radiation therapy in patients with advanced non-small-cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), or squamous-cell carcinoma of the head and neck (SCCHN), Benjamin Cooper, David B Page, and See full list of authors in comments
For Ethical Fundraising from Patients, Respect them as Partners., Brendan Curti
Chapter 72: Cancer of the Skin, Brendan Curti, Sancy Leachman, and Walter Urba
Dose escalation of davoceticept, a conditional CD28 costimulator and dual checkpoint inhibitor, in advanced malignancies (NEON-1), Diwakar Davar, Rachel E Sanborn, and See full list of authors in comments
Phase 1 study of SEA-TGT, a human, nonfucosylated monoclonal antibody directed to TIGIT with enhanced immune effector function, in patients with advanced malignancies (SGNTGT-001, trial in progress), D Davar, Rachel E Sanborn, and See full list of authors in comments
PD-1 and ICOS co-expression identifies tumor-reactive CD4 T cells in human solid tumors., Rebekka Duhen, Olivier Fesneau, Kimberly Samson, Alexandra K Frye, Michael Beymer, Venkatesh Rajamanickam, David Ross, Eric Tran, Brady Bernard, Andrew D Weinberg, and Thomas Duhen
OX40 boosts and sustains humoral and cellular immune responses to SARS-CoV-2 spike protein and RNA vaccinations, R Duhen, Bernard A Fox, Andrew D Weinberg, and See all authors in comments
PD-1 and ICOS co-expression identifies tumor-reactive CD4 T cells in human solid tumors, Thomas Duhen
Real-world burden of chemotherapy-induced myelosuppression in patients with small cell lung cancer: a retrospective analysis of electronic medical data from community cancer care providers., Robert S. Epstein, Roshanthi Weerasinghe, Amy S. Parrish, JoAnn Krenitsky, Rachel E Sanborn, and Tehseen Salimi
T Cells Engineered to Express Immunoreceptors Targeting the Frequently Expressed Medullary Thyroid Cancer Antigens Calcitonin, CEA, and RET M918T., Timothy A Erickson, Yi-Ping Shih, Joseph Fass, Myungkyu Jang, and Eric Tran
A Phase II, Single-arm Trial of Sunitinib and Erlotinib in Advanced Renal Cell Carcinoma., Zizhen Feng, Brendan Curti, David I Quinn, John M Strother, Zunqiu Chen, Rebecca Agnor, Tomasz M Beer, and Christopher W Ryan
Phase II Randomized Trial of Transoral Surgery and Low-Dose Intensity Modulated Radiation Therapy in Resectable p16+ Locally Advanced Oropharynx Cancer: An ECOG-ACRIN Cancer Research Group Trial (E3311)., Robert L Ferris, Yael Flamand, Gregory S Weinstein, Shuli Li, Harry Quon, Ranee Mehra, Joaquin J Garcia, Christine H Chung, Maura L Gillison, Umamaheswar Duvvuri, Bert W O'Malley, Enver Ozer, Giovana R Thomas, Wayne M Koch, Neil D Gross, Richard Bryan Bell, Nabil F Saba, Miriam Lango, Eduardo Méndez, and Barbara Burtness
Identification of a subset of tumor-reactive CD8 TIL expressing NKG2A in HNSCC and CRC, O Fesneau, K Samson, V Rajamanickam, D Ross, and Thomas Duhen
Recommended phase 2 dose (RP2D) of HB-200 arenavirus-based cancer immunotherapies in patients with HPV16+ cancers., Siqing Fu, Rom Leidner, and Matthew H Taylor
A phase 2 study of an off-the-shelf, multi-neoantigen vector (ADXS-503) in patients with metastatic non–small cell lung cancer either progressing on prior pembrolizumab or in the first-line setting., Gregory James Gerstner, Rachel E Sanborn, and See full list of authors in comments
A phase 1b, multicenter, dose-escalation study of subasumstat (TAK-981) in combination with pembrolizumab in patients (pts) with advanced solid tumors., Sanjay Goel, Rachel E Sanborn, and See full list of authors in comments
Safety and tolerability of MEDI0562, an OX40 agonist monoclonal antibody, in combination with durvalumab or tremelimumab in adult patients with advanced solid tumors., Jonathan W Goldman, Sarina A Piha-Paul, Brendan Curti, Katrina S Pedersen, Todd M Bauer, Stefanie L Groenland, Richard D Carvajal, Vaishali Chhaya, Gray Kirby, Kelly McGlinchey, Scott A Hammond, Katie L Streicher, Danielle Townsley, Young Kwang Chae, Jens Voortman, Aurelien Marabelle, and John Powderly
Fluorescence tagging to monitor CD8 T cell recirculation from the tumor to the tumor-draining lymph node: the impact of focal radiation therapy on recirculation, Michael J. Gough
Tumor resident memory CD8 T cell formation and concomitant tumor immunity is CD40L dependent and CD4 independent, Michael J. Gough
The paradox of radiation and T cells in tumors., Michael J. Gough and Marka R Crittenden
Durability of B and T cell responses against a spike protein of SARS-CoV2 elicited by mRNA vaccines, LT Hamilton, Bernard A Fox, William L. Redmond, Brian D. Piening, and See full list of authors in comments
Proteogenomic Characterization of Head and Neck Squamous Cell Cancer Immunopeptidomes to Detect Non Canonical Protein Targets for Cancer Immunotherapy., N Iwamoto, Richard Bryan Bell, Carlo Bifulco, Walter Urba, Rom Leidner, Brian D. Piening, Bernard A Fox, and See full author list in comments
A rapid and universal liquid chromatograph-mass spectrometry-based platform, refmAb-Q nSMOL, for monitoring monoclonal antibody therapeutics., Noriko Iwamoto, Yoshinobu Koguchi, Kotoko Yokoyama, Akinobu Hamada, Atsushi Yonezawa, Brian D Piening, Eric Tran, Bernard A Fox, William L Redmond, and Takashi Shimada
Mid-pregnancy immune dysregulation and its association with maternal metabolic and genetic factors in those with preterm birth: Insights using artificial intelligence., L Jelliffe-Pawlowski, Brian D. Piening, and See full list of authors in comments
Interim results of an ongoing phase 1/2a study of HPN328, a tri-specific, half-life extended, DLL3-targeting, T-cell engager, in patients with small cell lung cancer and other neuroendocrine cancers., Melissa Lynne Johnson, Rachel E Sanborn, and See full list of authors in comments
Ex vivo analysis of radiation effects on tumor infiltrating immune cells using tumor explants, Aanchal Preet Kaur, Gwen Kramer, Marka R. Crittenden, and Michael J. Gough
Neoadjuvant Chemotherapy, Excision, and Observation for Early Rectal Cancer: The Phase II NEO Trial (CCTG CO.28) Primary End Point Results., Hagen F Kennecke, Chris J O'Callaghan, Jonathan M Loree, Hussein Moloo, Rebecca Auer, Derek J Jonker, Manoj Raval, Reilly Musselman, Grace Ma, Antonio Caycedo-Marulanda, Vlad V Simianu, Sunil Patel, Lacey D Pitre, Ramzi Helewa, Vallerie L Gordon, Katerina Neumann, Halla Nimeiri, Max Sherry, Dongsheng Tu, and Carl J Brown
A Novel Class of On-Treatment Cancer Immunotherapy Biomarker: Trough Levels of Antibody Therapeutics in Peripheral Blood., Yoshinobu Koguchi and William L Redmond
Factors impacting genomic testing rates among epithelial ovarian cancer patients across a large community-based healthcare system (595), Nicole Kretzer, Christopher J. Darus, Nancy Biery, Roshanthi Weerasinghe, Hsin-Fang Li, Ann Vita, Shwetha Pindikuri, Amy Parrish, Charles Drescher, and Fernanda Musa
Frequency of homologous recombination deficiency in a large community-based cohort of epithelial ovarian cancer cases (597), Nicole Kretzer, Fernanda Musa, Christopher Darus, Nancy Biery, Roshanthi Weerasinghe, Hsin-Fang Li, Ann Vita, Shwetha Pindikuri, Amy Parrish, and Charles Drescher
Neoantigen T-Cell Receptor Gene Therapy in Pancreatic Cancer., Rom Leidner, Nelson Sanjuan Silva, Huayu Huang, David Sprott, Chunhong Zheng, Yi-Ping Shih, Amy Leung, Roxanne Payne, Kim Sutcliffe, Julie Cramer, Steven A Rosenberg, Bernard A Fox, Walter Urba, and Eric Tran
CT502 - Preliminary immunological monitoring of first-in-human immunotherapy-trio for advanced head and neck squamous cell carcinoma, Rom Leidner, Matthew H Taylor, William L. Redmond, Brady Bernard, Richard Bryan Bell, Walter Urba, Carlo Bifulco, Brian D. Piening, Bernard A Fox, and See full authors list in comments
Angiotensin receptor blockade and stereotactic body radiation therapy for early stage lung cancer ARB & SBRT for early stage lung cancer., Lauren T Maloney, Emile Latour, Yiyi Chen, Douglas Rice, Alison Grossblatt-Wait, Nima Nabavizadeh, Charles R Thomas, Kristina H Young, Joshua M Walker, John Holland, and Aaron J Grossberg
A single-arm, phase 2 study of perioperative ipilimumab, nivolumab, and cryoablation in women with hormone receptor-negative, HER2-negative, early-stage/resectable breast cancer., Heather L. McArthur, David B Page, and See full list of authors in comments
Neoadjuvant HER2-targeted therapy +/- immunotherapy with pembrolizumab (neoHIP): An open-label randomized phase II trial., Heather L. McArthur, David B Page, and See full list of authors in comments
Outcomes by tobacco history in E3311, a phase II trial of transoral surgery (TOS) followed by pathology-based adjuvant treatment in HPV-associated (HPV+) oropharynx cancer (OPC): A trial of the ECOG-ACRIN Cancer Research Group., Ranee Mehra, Richard Bryan Bell, and See full list of authors in comments
Immunological profiling of tumor-infiltrating CD8+ T lymphocytes in primary non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), breast cancer (BCa), and renal cell cancers (RCC)., W Miller, William L. Redmond, and See full list of authors in comments
CT041 - Monotherapy dose escalation of davoceticept (ALPN-202), a conditional CD28 costimulator and dual checkpoint inhibitor, in advanced malignancies (NEON-1), Michael Millward, Rachel E Sanborn, and See full list of authors in comments
Clinical Performance of the Consensus Immunoscore in Colon Cancer in the Asian Population from the Multicenter International SITC Study., Bernhard Mlecnik, Toshihiko Torigoe, Gabriela Bindea, Boryana Popivanova, Mingli Xu, Tomonobu Fujita, Shoichi Hazama, Nobuaki Suzuki, Hiroaki Nagano, Kiyotaka Okuno, Yoshihiko Hirohashi, Tomohisa Furuhata, Ichiro Takemasa, Prabhudas Patel, Hemangini Vora, Birva Shah, Jayendrakumar B Patel, Kruti N Rajvik, Shashank J Pandya, Shilin N Shukla, Yili Wang, Guanjun Zhang, Takayuki Yoshino, Hiroya Taniguchi, Carlo Bifulco, Alessandro Lugli, Jiun-Kae Jack Lee, Inti Zlobec, Tilman T Rau, Martin D Berger, Iris D Nagtegaal, Elisa Vink-Börger, Arndt Hartmann, Carol I Geppert, Julie Kolwelter, Susanne Merkel, Robert Grützmann, Marc Van den Eynde, Anne Jouret-Mourin, Alex Kartheuser, Daniel Léonard, Christophe Remue, Julia Wang, Prashant Bavi, Michael H A Roehrl, Pamela S Ohashi, Linh T Nguyen, SeongJun Han, Heather L MacGregor, Sara Hafezi-Bakhtiari, Bradly G Wouters, Giuseppe V Masucci, Emilia Andersson, Eva Zavadova, Michal Vocka, Jan Spacek, Lubos Petruzelka, Bohuslav Konopasek, Pavel Dundr, Helena Skalova, Kristyna Nemejcova, Gerardo Botti, Fabiana Tatangelo, Paolo Delrio, Gennaro Ciliberto, Michele Maio, Luigi Laghi, Fabio Grizzi, Florence Marliot, Tessa Fredriksen, Bénédicte Buttard, Lucie Lafontaine, Pauline Maby, Amine Majdi, Assia Hijazi, Carine El Sissy, Amos Kirilovsky, Anne Berger, Christine Lagorce, Christopher Paustian, Carmen Ballesteros-Merino, Jeroen Dijkstra, Carlijn Van de Water, Shannon van Lent-van Vliet, Nikki Knijn, Ana-Maria Mușină, Dragos-Viorel Scripcariu, Francesco M Marincola, Paolo A Ascierto, Bernard A Fox, Franck Pagès, Yutaka Kawakami, and Jérôme Galon
CT250 / 11 - A first-in-human phase 1 study of NL-201 in patients with relapsed or refractory cancer, Aung Naing, Brendan Curti, and See full list of authors in comments
The Human Tumor Atlas Network's beginning steps toward the future of collaborative multi-omic discovery., David B Page
Brain radiotherapy, tremelimumab-mediated CTLA-4-directed blockade +/- trastuzumab in patients with breast cancer brain metastases., David B Page, Kathryn Beal, Stefanie N Linch, Kateri Spinelli, Micaela Rodine, Darragh Halpenny, Shanu Modi, Sujata Patil, Robert J Young, Thomas Kaley, Taha Merghoub, David Redmond, Phillip Wong, Christopher A Barker, Adi Diab, Larry Norton, and Heather L McArthur
Real-World Evidence Insights in Cancer Research and Care, Brian D. Piening
Pathogenic fusion detection in solid malignancies utilizing RNA-DNA based comprehensive genomic profiling (CGP) testing., Brian D. Piening, Alexa K Dowdell, Ryan Meng, Ann Vita, Roshanthi Weerasinghe, Alisha Stein, Bela Bapat, Brock Shroeder, Shu-Ching Chang, Lauren Harold, Mark Schmidt, Thomas R. Ward, Josiah T Wagner, Stanley Piotrowski, Phillip G. Febbo, and Carlo Bifulco
Elucidating Diversity in Obesity-Related Phenotypes Using Longitudinal and Multi-omic Approaches, Brian D. Piening, Alexa K Dowdell, and Michael P. Snyder
Whole transcriptome profiling of prospective endomyocardial biopsies reveals prognostic and diagnostic signatures of cardiac allograft rejection., Brian D. Piening, Alexa K Dowdell, Mengqi Zhang, Bao-Li Loza, David Walls, Hui Gao, Maede Mohebnasab, Yun Rose Li, Eric Elftmann, Eric Wei, Divya Gandla, Hetal Lad, Hassan Chaib, Nancy K Sweitzer, Mario Deng, Alexandre C Pereira, Martin Cadeiras, Abraham Shaked, Michael P Snyder, and Brendan J Keating
CT209 / 9 - A first-in-human phase 1 trial of IO-108, an antagonist antibody targeting LILRB2 (ILT4), as monotherapy and in combination with pembrolizumab in adult patients with advanced relapsed or refractory solid tumors (NCT05054348), John Powderly, Matthew H Taylor, and See full list of authors in comments
Multimodal single-cell analysis of human TILs across multiple tumor types reveals heterogeneity and potential opportunities for personalized immunotherapy, William L. Redmond
Novel mechanisms to augment the efficacy of cancer immunotherapy, William L. Redmond
Multimodal single-cell analysis of human tumor infiltrating immune cells across multiple tumor types reveals heterogeneity and potential opportunities for personalized immunotherapeutic strategies., William L. Redmond and See full list of authors in comments
Combining bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) improves systemic antitumor CD8, Annah S Rolig, Daniel Rose, Grace Helen McGee, Werner Rubas, Saul Kivimäe, and William L. Redmond
Response to anti-PD-1 and anti-LAG-3 immune checkpoint blockade is associated with induction of pro-inflammatory Tregs., AS Rolig, William L. Redmond, and See full list of authors in comments
Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors., Rachel E Sanborn, Michael J Pishvaian, Margaret K Callahan, Amy Weise, Branimir I Sikic, Osama Rahma, Daniel C Cho, Naiyer A Rizvi, Mario Sznol, Jose Lutzky, Julie E Bauman, Rhonda L Bitting, Alexander Starodub, Antonio Jimeno, David A Reardon, Thomas Kaley, Fabio Iwamoto, Joachim M Baehring, Deepa S Subramaniam, Jeanny B Aragon-Ching, Thomas R Hawthorne, Tracey Rawls, Michael Yellin, and Tibor Keler
Beyond Checkpoint Inhibitors: Enhancing Antitumor Immune Response in Lung Cancer, Rachel E Sanborn and See full list of authors in comments
Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study., Alison Sehgal, Daanish Hoda, Peter A Riedell, Nilanjan Ghosh, Mehdi Hamadani, Gerhard C Hildebrandt, John E Godwin, Patrick M Reagan, Nina Wagner-Johnston, James Essell, Rajneesh Nath, Scott R Solomon, Rebecca Champion, Edward Licitra, Suzanne Fanning, Neel Gupta, Ronald Dubowy, Aleco D'Andrea, Lei Wang, Ken Ogasawara, Jerill Thorpe, and Leo I Gordon
Immunotherapy in head and neck squamous cell carcinoma: a narrative review., Shay Sharon and R Bryan Bell
Amivantamab and lazertinib in patients with EGFR-mutant non–small cell lung (NSCLC) after progression on osimertinib and platinum-based chemotherapy: Updated results from CHRYSALIS-2., Catherine A. Shu, Rachel E Sanborn, and See full list of authors in comments
3380 / 8 - Seven autoantibody panel, validated in two independent patient serum collections, can detect women with DCIS and invasive breast cancer, Sasha Stanton and See full list of authors in comments
Neoadjuvant survivin-targeted immunotherapy maveropepimut-S (MVP-S) to increase Th1 immune response in Ki67-high hormone receptor-positive (HR+) early-stage breast cancer (ESBC)., Sasha Stanton, Kristina H Young, David B Page, and See all authors in comments
Targeting mutant KRAS with TCR-gene therapy, Eric Tran
Neoantigen T-Cell Receptor Gene Therapy in Pancreatic Cancer. Reply., Eric Tran, Walter Urba, and Rom Leidner
Editorial: Mechanisms of Lymphocyte Exclusion in the Tumor Microenvironment., Rieneke van de Ven, Carlo Bifulco, Jason J Luke, and Sarah E Church
Neoantigen-specific CD4 + T cells in human melanoma have diverse differentiation states and correlate with CD8 + T cell, macrophage, and B cell function, Joshua R Veatch, Sylvia M Lee, Carolyn Shasha, Naina Singhi, Julia L Szeto, Ata S Moshiri, Teresa S Kim, Kimberly Smythe, Paul Kong, Matthew Fitzgibbon, Brenda Jesernig, Shailender Bhatia, Scott S Tykodi, Evan T Hall, David R Byrd, John A Thompson, Venu G Pillarisetty, Thomas Duhen, A McGarry Houghton, Evan Newell, Raphael Gottardo, and Stanley R Riddell
Identification of clinically actionable biomarkers via routine comprehensive genomic profiling across a large community health system, Roshanthi Weerasinghe, Ryan Meng, Alexa K Dowdell, Bela Bapat, Ann Vita, Brock Schroeder, Alisha Stein, Lauren Harold, Mark Schmidt, Shu-Ching Chang, Thomas R. Ward, Josiah T Wagner, Stanley Piotrowski, Phillip G. Febbo, Carlo Bifulco, and Brian D. Piening
Identifying tumor-reactive CD8+ TIL in patients with solid malignancies: clinical implications, Andrew D Weinberg
T Cell Agonists, Andrew D Weinberg
Current Clinical Trial Landscape of OX40 Agonists., Rashi Yadav and William L. Redmond
Galunisertib plus neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer: a single-arm, phase 2 trial., Tomoko Yamazaki, Andrew J Gunderson, Miranda Gilchrist, Mark Whiteford, Maria X Kiely, Amanda Hayman, David O'Brien, Rehan Ahmad, Jeffrey V Manchio, Nathaniel E Fox, Kayla McCarty, Michaela Phillips, Evelyn Brosnan, Gina Vaccaro, Rui Li, Miklos Simon, Eric Bernstein, Mary McCormick, Lena Yamasaki, Yaping Wu, Ashley Drokin, Trevor Carnahan, Yy To, William L. Redmond, Brian Lee, Jeannie Louie, Eric Hansen, Matthew C Solhjem, Julie Cramer, Walter Urba, Michael J. Gough, Marka R Crittenden, and Kristina H Young
Submissions from 2021
Listeria monocytogenes-infected human monocytic derived dendritic cells activate Vγ9Vδ2 T cells independently of HMBPP production., Alejandro F Alice, Gwen Kramer, Shelly Bambina, Keith S Bahjat, Michael J Gough, and Marka R Crittenden
Clinical Responses of Oncolytic Coxsackievirus A21 (V937) in Patients With Unresectable Melanoma., Robert H I Andtbacka, Brendan Curti, Gregory A Daniels, Sigrun Hallmeyer, Eric D Whitman, Jose Lutzky, Lynn E Spitler, Karl Zhou, Praveen K Bommareddy, Mark Grose, Meihua Wang, Cai Wu, and Howard L Kaufman
Perspectives in immunotherapy: meeting report from the immunotherapy bridge (December 2nd-3rd, 2020, Italy)., Paolo A Ascierto, Carlo Bifulco, Fortunato Ciardiello, Sandra Demaria, Leisha A Emens, Robert Ferris, Silvia C Formenti, Jerome Galon, Samir N Khleif, Tomas Kirchhoff, Jennifer McQuade, Kunle Odunsi, Akash Patnaik, Chrystal M Paulos, Janis M Taube, John Timmerman, Bernard A Fox, Patrick Hwu, and Igor Puzanov
The State of Melanoma: Emergent Challenges and Opportunities., Michael B Atkins, Clara Curiel-Lewandrowski, David E Fisher, Susan M Swetter, Hensin Tsao, Julio A Aguirre-Ghiso, Maria S Soengas, Ashani T Weeraratna, Keith T Flaherty, Meenhard Herlyn, Jeffrey A Sosman, Hussein A Tawbi, Anna C Pavlick, Pamela B Cassidy, Sunandana Chandra, Paul B Chapman, Adil Daud, Zeynep Eroglu, Laura K Ferris, Bernard A Fox, Jeffrey E Gerhsenwald, Geoffrey T Gibney, Douglas Grossman, Brent A Hanks, Douglas Hanniford, Eva Hernando, Joanne M Jeter, Douglas B Johnson, Samir N Khleif, John M Kirkwood, Sancy A Leachman, Darren Mays, Kelly C Nelson, Vernon K Sondak, Ryan J Sullivan, and Glenn Merlino
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing): A phase III trial—ECOG-ACRIN EA6134, Michael B. Atkins, Brendan Curti, and See full list of authors in comments
Arginase therapy combines effectively with checkpoint blockade or agonist anti-OX40 immunotherapy to control tumor growth., Mark D Badeaux, Annah S Rolig, Giulia Agnello, Danlee Enzler, Melissa Kasiewicz, Leslie Priddy, Jason F Wiggins, Alexander Muir, Mark R Sullivan, Jessica Van Cleef, Christopher Daige, Matthew G Vander Heiden, Venkatesh Rajamanickam, James Wooldridge, William L. Redmond, and Scott W Rowlinson
Immune-based mutation classification enables neoantigen prioritization and immune feature discovery in cancer immunotherapy., Peng Bai, Yongzheng Li, Qiuping Zhou, Jiaqi Xia, Peng-Cheng Wei, Hexiang Deng, Min Wu, Sanny K Chan, John W Kappler, Yu Zhou, Eric Tran, Philippa Marrack, and Lei Yin
SARS-CoV-2 antibodies detected in human breast milk postvaccination, Jill K. Baird, Shawn M. Jensen, Walter Urba, Bernard A Fox, and Jason R Baird
Amivantamab in combination with lazertinib for the treatment of osimertinib-relapsed, chemotherapy-naïve EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC) and potential biomarkers for response., Joshua Bauml, Byoung Chul Cho, Rachel E Sanborn, and See full author list in comments
10. Dendritic cell migration is required for the immunological responsiveness of tumors to radiation therapy, TC Blair, G Kramer, S Bambina, A Dowdell, AF Alice, Brian D. Piening, Marka R Crittenden, and MJ Gough
165 Generating enhanced tumor infiltrating lymphocytes through microfluidic cell squeezing, Devin Bridgen, Andrew D Weinberg, and See full list of authors in comments
Implications of Selection Bias Due to Delayed Study Entry in Clinical Genomic Studies., Samantha Brown, Jessica A Lavery, Ronglai Shen, Axel S Martin, Kenneth L Kehl, Shawn M Sweeney, Eva M Lepisto, Hira Rizvi, Caroline G McCarthy, Nikolaus Schultz, Jeremy L Warner, Ben Ho Park, Philippe L Bedard, Gregory J Riely, Deborah Schrag, Katherine S Panageas, AACR Project GENIE Consortium, Walter Urba, Brady Bernard, Brian D. Piening, and Carlo Bifulco
A first-in-human study of AO-176, a highly differentiated anti-CD47 antibody, in patients with advanced solid tumors., Howard A. Burris III, Alexander I. Spira, and Matthew H Taylor
Portable air-fed cold atmospheric plasma device for postsurgical cancer treatment., Guojun Chen, Zhitong Chen, Zejun Wang, Richard Obenchain, Di Wen, Hongjun Li, Richard E Wirz, and Zhen Gu
Impact of new cancer therapies on outpatient treatment delivery for colorectal cancer: A population-based study., Leo Chen, Caroline H Speers, Winson Y Cheung, John J Spinelli, and Hagen F Kennecke
Secondary Correction of Midface Fractures., Jonathan Chodroff, Nadir Elias, Michael Whitcomb, Cong Vo, and Richard Bryan Bell
94 Effects of chemoimmunotherapy on the peripheral blood: insights from immune monitoring of a phase Ib trial of pembrolizumab and paclitaxel or capecitabine for triple-negative breast cancer (TNBC), Brie Chun, Joanna Pucilowska, Shu-Ching Chang, Isaac Kim, Benjamin Nikitin, Yoshinobu Koguchi, William L. Redmond, Brady Bernard, Venkatesh Rajamanickam, Nathan Polaske, Paul Fields, Valerie Conrad, Mark Schmidt, Walter Urba, Alison Conlin, Heather McArthur, and David B Page
Long-term progression-free survival of patients with metastatic melanoma or renal cell carcinoma following high-dose interleukin-2., Joseph I Clark, Brendan Curti, Elizabeth J Davis, Howard Kaufman, Asim Amin, Ajjai Alva, Theodore F Logan, Ralph Hauke, Gerald P Miletello, Ulka Vaishampayan, Douglas B Johnson, Richard L White, Peter H Wiernik, and Janice P Dutcher
Interim results of viagenpumatucel-L (HS-110) plus nivolumab in previously treated patients (pts) with advanced non-small cell lung cancer (NSCLC) in two treatment settings., Roger B. Cohen, George E. Peoples, Rachel E Sanborn, and See list of authors in comments
Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumors., Kevin Conlon, Dionysios C Watson, Thomas A Waldmann, Antonio Valentin, Cristina Bergamaschi, Barbara K Felber, Cody J Peer, William D Figg, E Lake Potter, Mario Roederer, Douglas G McNeel, John A Thompson, Sumati Gupta, Rom Leidner, Andrea Wang-Gillam, Nehal S Parikh, Debby Long, Sema Kurtulus, Lang Ho Lee, Niladri Roy Chowdhury, Florent Bender, and George N Pavlakis
Combinations of stereotactic radiotherapy and immune checkpoint inhibition: Translational analyses, Marka R Crittenden
Integrating Radiation Therapy with Immunotherapy, Marka R Crittenden
